Life Science Leader Magazine Supplements

CMO 2017

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link: https://lifescienceleadermag.epubxp.com/i/792774

Contents of this Issue

Navigation

Page 56 of 81

K E Y W W W.C M O L E A D E R S H I PA W A R D S .C O M LIFESCIENCELEADER.COM THE CMO LEADERSHIP AWARDS 2017 55 CAPABILITIES COMPATIBILITY DEVELOPMENT EXPERTISE RELIABILITY QUALITY 2017 CMO LEADERSHIP AWARDS WINNERS Company Profiles DRUG LIFE CYCLE STAGES: Research & Development: Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3) Drug Substance Production: Primary Process Development, Drug Substance Production SERVICES & CAPABILITIES: generics, peptides, powders: non-sterile, powders: sterile, APIs, NCEs, RSMs, high value chiral intermediates, high value amino acids, key intermediates, building blocks, starting materials, process R&D, stability studies, analytical method development & validations "FLAMMA is family owned and run since 1950. Long term management stability helps to dif- ferentiate FLAMMA from other CMOs. Our two cGMP facilities in Italy and our new cGMP facil- ity in China give FLAMMA the ability to have a full control of the supply chain and to provide optimal service to customers. When it matters most, pharmaceutical companies continue to turn to FLAMMA! Thanks to those who recognized FLAMMA for these 2017 CMO Leadership Awards." DRUG TYPE: Pharmaceuticals GIAN PAOLO NEGRISOLI President & CEO CATEGORIES WON: FLAMMA Chignolo d'Isola, Bergamo, Italy www.flammagroup.com Phone: 011 39 035 4991811 Contact: Kenneth Drew, Ph.D. Email: ken.drew@flammagroup.com Key locations: Chignolo, Italy; Isso, Italy; Dalian Honkai, China INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, cultural fit, innovation, on- time, reputation, right first time, state-of-the-art, strength of science DRUG LIFE CYCLE STAGES: Research & Development: Clinical (Phase 2, Phase 3) Drug Substance Production: Primary Process Development, Drug Substance Production Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics "We are delighted to receive six awards this year, particularly as they are based on feedback from our clients. Our extensive expertise helps companies deliver products for their patients and customers. We offer the Pharma/Biopharma industry a fully integrated supply chain solution with FDA and EMA approved multi-product facilities providing multiple services. GSK works closely with our customers, matching their specific needs with our capabilities and facilities, from development through commercial production. We look forward to more successful col- laborations in the future." DRUG TYPE: Pharmaceuticals, Biopharmaceuticals JANICE L. GRAFF Director of Finished Product Sales & Business Development CATEGORIES WON: GlaxoSmithKline Contract Manufacturing Brentford, Middlesex, UK www.gsk.com Contact: Janice Graff Email: janice.l.graff@gsk.com Key locations: Australia, China, Europe, Japan, Middle East, North America, South America INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, cultural fit, innovation, on- time, reputation, right first time, state-of-the-art, strength of science DRUG LIFE CYCLE STAGES: Research & Development: Pre-Clinical, Clinical (Phase 1, Phase 2, Phase 3) Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging SERVICES & CAPABILITIES: capsules, controlled substances, creams & ointments, gels, generics, liquids, non-sterile, ophthalmics, OTC, peptides, powders: non-sterile, semisolids, solid dose, solutions & suspensions, sterile, sustained release, topicals "We see pharmaceutical outsourcing as a partner- ship and not just as the more traditional "suppli- er-customer" relationship. This view differentiates us from our competitors in our customers' eyes as they witness first hand our flexibility, expertise, and commitment to quality. In today's highly com- petitive and challenging healthcare environment, having a partner who understands the challenges our customers face is critical in ensuring a mutu- ally successful outcome." DRUG TYPE: Pharmaceuticals, Biopharmaceuticals LEE KARRAS Chief Executive Officer CATEGORIES WON: Halo Pharmaceuticals Whippany, NJ www.halopharma.com Phone: +1 973 428 4000 Contact: Louis Weber Email: lweber@halopharma.com Key locations: Whippany, NJ, USA; Montreal, Quebec, Canada INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, cultural fit, innovation, on- time, reputation, right first time, state-of-the-art, strength of science SERVICES & CAPABILITIES: API's (phase I-III), cephalosporins, cytotoxic & high pot. cpds, lyophi- lised prod., non-sterile, OTC, parenterals, peptides, proteins, aseptic fill/finish, capsules, injectables, liq- uids, powders: sterile, solid dose, semisolids, suspen- sions, sust. release, syringes: prefilled, tablets: bi- & tri-layer, process & analyt. dev., fermentation: bacteria & yeast, multiple harvest, downstream capture, purification & bulk fill, sterile liquids, & freeze-dried drug prod.

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine Supplements - CMO 2017